Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial

Adults with metastatic CRPC who progressed after androgen-deprivation therapy and one androgen receptor pathway inhibitor were randomly assigned 1:1 to pembrolizumab or placebo plus docetaxel with concomitant prednisone.